Aliskiren
Thuốc Gốc
Biotech
Tương Tác Thuốc :
- Alfuzosin Monitor therapy due to enhanced hypotensive effect of aliskiren.
- Amifostine Amifostine hypotensive effect can be exacerbated with administration of antihypertensives. If amifostine is administered, no antihypertensives should be administered within 24 hours. If the antihypertensives can't be withheld, amifostine should not be administered.
- Atorvastatin Therapy modification should be considered because atorvastatin increases aliskiren serum concentration.
- Brimonidine Monitor therapy because of enhanced hypotensive effect.
- Canagliflozin Monitor therapy because canagliflozin may enhance aliskiren antihypertensive and hyperkalemic effects.
- Cyclosporine Avoid combination because cyclosporine increases aliskiren serum concentration.
- Diazoxide Monitor therapy due to enhanced hypotensive effect of aliskiren.
- Duloxetine Monitor therapy due to enhanced orthostatic hypotensive effect of duloxetine.
- Furosemide Monitor therapy due to potential decreased serum concentration of furosemide.
- Heparin Monitor therapy due to enhanced hyperkalemic effect of aliskiren.
- Itraconazole Avoid combination due to increased serum concentration of aliskiren.
- Ketoconazole Monitor therapy due to increased serum concentration of aliskiren.
- Methylphenidate Monitor therapy due to reduced antihypertensive effect of aliskiren.
- Obinutuzumab Obinutuzumab antihypertensive effect may be enhanced. Administration of antihypertensives should be withheld 12 hours before infusion of obinutuzumab and 1 hour after the end of infusion.
- Pentoxifylline Monitor therapy due to enhanced antihypertensive effects of aliskiren.
- Rituximab Consider therapy modification due to enhanced hypotensive effect of rituximab.
- Verapamil Monitor therapy due to increased concentration of aliskiren.
- Yohimbine Monitor therapy due to decreased antihypertensive effects of aliskiren.
Tài Liệu Tham Khảo Thêm
drugbank
Bạn thấy hài lòng ?
Bạn chưa hài lòng ?
... loading
... loading